[{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Montanide ISA 51","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"Mount Sinai Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mount Sinai Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mount Sinai Hospital \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sinai Hospital \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"RV001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for RV001
Details :
RV001 (onilcamotide), peptide antigen against RhoC – is administered to patient through subcutaneous injection, encounters dendritic cells – type of white blood cell with regulatory functions in immune system – that capture, absorb and process RV00...
Details :
The safety profile of RV001 (onilcamotide) was considered excellent, and the DSMC concluded that the trial can continue without modifications and can significantly prevent or delay disease progression.
Details :
RV001, is an immuno-oncologic drug that is presented to the immune system as an antigen, stimulating T-cells to identify and destroy cells that carry this protein, i.e. metastatic or metastatic potential cells.
Details :
The objective of the study is to show that RV001 can significantly prevent or delay disease progression in these patients, something for which no standard therapy is available today.
Details :
The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for...
Details :
RhoVac reported that as Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination causing a delay in RhoVac's Phase IIb study.
Details :
BRaVac is a phase IIb randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatm...
Details :
The scientifically reviewed article reports that the treatment with RhoVac’s drug candidate RV001 was safe and well tolerated, and that a long-lasting immune response could be generated in the vast majority of patients.
Details :
The article will feature an elaboration on the mode of action of RV001, but also a discussion on the PSA data findings indicating possibilities of delaying disease progression, for which RhoVac’s currently ongoing phase IIb study is aimed at providing ...
Details :
The phase IIb-study is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent tre...
Reset All
